Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BioCryst Pharma Q2 2024 GAAP EPS $(0.06) Beats $(0.18) Estimate, Sales $109.332M Beat $98.319M Estimate

Author: Benzinga Newsdesk | August 05, 2024 07:02am

Posted In: BCRX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist